MedTrace Logo

O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus

NCT04440566 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-01-19

No results posted yet for this study

Summary

This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.

Conditions

Interventions

BIOLOGICAL

blood sample

30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Patrick BLANCO, Prof · University Hospital, Bordeaux

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2022-02-14
Completion
2022-02-14

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04440566 on ClinicalTrials.gov